- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04906629
INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees (Boost-EBOV)
Phase Ib, Placebo-controlled Randomized Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of INO-4201 Followed by Electroporation as a Booster Vaccination in Healthy Volunteers Who Have Previously Received the VSV-ZEBOV Vaccine
Ebola virus disease (EVD) is a serious illness with a high fatality rate. Currently only one vaccine is available, VSV-ZEBOV/Ervebo; this vaccine is clinically effective and has been deployed as a preventive measure during recent Ebola outbreaks. The durability of protection afforded by this vaccine is unknown, however, and it is thought that a booster vaccination may be required to maintain immune responses. Recently, a synthetic DNA vaccine, INO-4201, was tested in humans and showed good immunogenicity and an enhanced safety profile.
This study aims to test whether the DNA-based candidate INO-4201 can be used as a booster in healthy volunteers previously vaccinated with VSV-ZEBOV.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This randomized placebo-controlled phase 1b trial will evaluate the safety, tolerability and immunogenicity of the DNA-based vaccine candidate INO-4201 in healthy adult volunteers who previously received a single injection of VSV-ZEBOV. These participants will be randomized to either INO-4201 or placebo, injected once intradermally (ID) followed by electroporation (EP) with the CELLECTRA2000 device. Volunteers will be observed for 1 hour after vaccination and will attend follow-up visits at the Clinical Trials Unit in the 24 weeks after injection (8 visits in all).
Primary outcome parameters are (i) the incidence of adverse events in relationship with INO-4201 from day 0 to 14, and (ii) geometric mean titers (GMT) of EBOV-GP-binding IgG antibodies at 4 weeks post-injection.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Geneva, Switzerland, 1205
- Geneva University Hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has provided written informed consent prior to screening
- Males and females ≥ 18 years old
- Previously vaccinated with a single dose of VSV-ZEBOV at any dose between 10^5 and 10^8 pfu more than 6 months prior to inclusion
- Free of clinically significant health problems, as determined by pertinent medical history and clinical examination at study screening
- Has an acceptable site for ID electroporation considering the deltoid and anterolateral quadriceps muscles
- Is post-menopausal, or surgically sterile, or has a partner who is sterile, or uses a medically effective contraception with a failure rate of <1% per year when used consistently and correctly from screening until 6 months following last dose.
Exclusion Criteria:
- Female volunteers who are pregnant or breastfeeding at screening or prior to dosing
- Administration of an investigational compound either currently or within 30 days of Day 0
- Prisoner or volunteers who are compulsorily detained (involuntary incarceration) for treatment of either a physical or psychiatric illness
- Active drug or alcohol or substance abuse or dependence
- Planned administration of another Ebola vaccine (including rVSV-ZEBOV and Ad26/MVA-BN-Filo vaccines) during the study period
- Administration of a live vaccine in the 21 days or an inactivated vaccine in the 14 days before planned injection
- Current or anticipated concomitant immunosuppressive therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, or low-dose methotrexate). Systemic corticosteroids must be discontinued at least 4 weeks prior to first dose.
Temporary exclusion criteria:
- Acute disease at the time of randomization
- Active skin lesions at the potential injection site
- Temperature ≥38.0°C at the time of randomization
- Recent receipt of a SARS-CoV-2 vaccine with final dose <4 weeks prior
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: INO-4201
One intradermal injection of INO-4201 followed by electroporation
|
One dose of 1 mg of INO-4201 in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
|
Placebo Comparator: Placebo
One intradermal injection of normal saline followed by electroporation
|
One dose of normal saline in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events by systemic organ class, preferred term, severity and relationship to investigational product INO-4201 from day 0 to day 14.
Time Frame: Days 0 - 14
|
Primary safety outcome
|
Days 0 - 14
|
Quantitative EBOV-GP-binding IgG antibody responses (GMTs as measured by ELISA) at 4 weeks after injection
Time Frame: Days 0 - 28
|
Primary immunogenicity outcome
|
Days 0 - 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of solicited local and systemic reactogenicity signs and symptoms
Time Frame: Days 0 - 14
|
Secondary safety outcome
|
Days 0 - 14
|
Occurrence of unsolicited adverse events
Time Frame: Days 0 - 28
|
Secondary safety outcome
|
Days 0 - 28
|
Occurrence of serious adverse events (SAE)
Time Frame: Days 0 - 168
|
Secondary safety outcome
|
Days 0 - 168
|
GMTs of EBOV-GP-binding antibodies as measured by ELISA
Time Frame: Weeks 2, 12, 24
|
Secondary immunogenicity outcome
|
Weeks 2, 12, 24
|
GMTs of neutralizing antibodies
Time Frame: Weeks 2, 4, 12, 24
|
Secondary immunogenicity outcome
|
Weeks 2, 4, 12, 24
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-02774
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ebola Virus Disease
-
National Institute of Allergy and Infectious Diseases...CompletedEbola Virus Disease | Ebola Hemorrhagic Fever | Ebola Virus Vaccines | Envelope Glycoprotein, Ebola Virus | FilovirusUnited States
-
Jiangsu Province Centers for Disease Control and...Beijing Institute of Biotechnology; Tianjin Cansino Biotechnology IncCompletedEbola DiseaseSierra Leone
-
Cerus CorporationTerminated
-
National Institute of Allergy and Infectious Diseases...CompletedEbola VirusUnited States, Congo, The Democratic Republic of the
-
National Institute of Allergy and Infectious Diseases...CompletedEbola Virus Disease | Ebola Vaccines | Marburg Virus Disease | Marburgvirus | EbolavirusUnited States
-
London School of Hygiene and Tropical MedicineCompletedHiv | Ebola Virus Disease | EbolaKenya, Uganda
-
Janssen Vaccines & Prevention B.V.Institut National de la Santé Et de la Recherche Médicale, France; University...CompletedEbola Viral DiseaseFrance, United Kingdom
-
MRC/UVRI and LSHTM Uganda Research UnitMinistry of Health, UgandaRecruiting
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University... and other collaboratorsNot yet recruiting
Clinical Trials on INO-4201
-
Inovio PharmaceuticalsGeneOne Life Science, Inc.; Defense Advanced Research Projects AgencyCompleted
-
Inovio PharmaceuticalsUniversity of PennsylvaniaCompletedAerodigestive Precancerous Lesions and MalignanciesUnited States
-
Inovio PharmaceuticalsCompleted
-
Inovio PharmaceuticalsMayo Clinic; University of Pennsylvania; University of Pittsburgh; Thomas Jefferson... and other collaboratorsCompletedBreast Cancer | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | ColoRectal Cancer | HepatoCellular CarcinomaUnited States
-
Moroccan Society of SurgeryInstitut National d'Oncologie Sidi Mohammed Ben AbdellahCompletedLearning OrganizationMorocco
-
Inovio PharmaceuticalsWithdrawnCoronavirus Infection
-
University of PennsylvaniaInovio PharmaceuticalsRecruiting
-
Inovio PharmaceuticalsCompletedCervical CancerUnited States
-
Inovio PharmaceuticalsUniversity of PennsylvaniaCompletedHead and Neck Squamous Cell CancerUnited States
-
Inovio PharmaceuticalsActive, not recruitingUrothelial CarcinomaUnited States, Spain